Cégbemutató
Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that can have a therapeutic or preventive benefit and have the potential to address a broad spectrum of diseases. Moderna’s platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing the Company the capability to pursue in parallel a robust pipeline of new development candidates. Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune and inflammatory diseases, independently and with strategic collaborators.
Igazgatóság & Felügyelőbizottság
CEO |
Stéphane Bancel |
Igazgatóság |
Jamey Mock, Stephen Hoge, M.D., Jerh Collins, Ph.D., Kate Cronin, Tracey Franklin, Shannon Thyme Klinger, Brad Miller |
Felügyelőbizottság |
Dr. Noubar Afeyan, Stéphane Bancel, Sandra Horning, M.D., Abbas Hussain, Elizabeth Nabel, M.D., François Nader, M.D., David Rubenstein, Paul Sagan, Elizabeth Tallett, Henri A. Termeer |
Cégadat
Név: |
Moderna Inc. |
Cím: |
200 Technology Square,Cambridge, Massachusetts 02139, USA |
Telefon: |
+1-617-714-6500 |
Fax: |
+1-617-583-1998 |
E-mail: |
info@modernatx.com
|
Internet: |
https://www.modernatx.com/ |
Ipar: |
Biotechnológia |
Szektor: |
Biotechnológia |
Alszektor: |
Biotechnológia |
Pénzügyi év vége: |
12. 31. |
Közkézhányad: |
- |
IPO dátum: |
2018. 12. 07. |
Befektetői kapcsolatok
Név: |
- |
IR telefon: |
- |
IR Fax: |
- |
IR e-mail: |
IR@modernatx.com
|